As of 2026-04-06, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (29.46) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.59 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -5121.4%.
The range of the Relative Valuation is (28.04) - (29.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.4x - 24.3x | 22.4x |
| Forward P/E multiples | 20.8x - 21.9x | 21.4x |
| Fair Price | (28.04) - (29.52) | (29.46) |
| Upside | -4880.1% - -5132.9% | -5121.4% |
| Date | P/E |
| 2026-04-02 | -0.44 |
| 2026-04-01 | -0.45 |
| 2026-03-31 | -0.42 |
| 2026-03-30 | -0.40 |
| 2026-03-27 | -0.42 |
| 2026-03-26 | -0.45 |
| 2026-03-25 | -0.45 |
| 2026-03-24 | -0.46 |
| 2026-03-23 | -0.46 |
| 2026-03-20 | -0.45 |
| 2026-03-19 | -0.48 |
| 2026-03-18 | -0.45 |
| 2026-03-17 | -0.48 |
| 2026-03-16 | -0.47 |
| 2026-03-13 | -0.45 |
| 2026-03-12 | -0.47 |
| 2026-03-11 | -0.44 |
| 2026-03-10 | -0.45 |
| 2026-03-09 | -0.46 |
| 2026-03-06 | -0.45 |
| 2026-03-05 | -0.46 |
| 2026-03-04 | -0.45 |
| 2026-03-03 | -0.45 |
| 2026-03-02 | -0.44 |
| 2026-02-27 | -0.43 |
| 2026-02-26 | -0.45 |
| 2026-02-25 | -0.43 |
| 2026-02-24 | -0.41 |
| 2026-02-23 | -0.41 |
| 2026-02-20 | -0.41 |
| 2026-02-19 | -0.44 |
| 2026-02-18 | -0.38 |
| 2026-02-17 | -0.39 |
| 2026-02-13 | -0.38 |
| 2026-02-12 | -0.40 |
| 2026-02-11 | -0.42 |
| 2026-02-10 | -0.42 |
| 2026-02-09 | -0.42 |
| 2026-02-06 | -0.42 |
| 2026-02-05 | -0.37 |
| 2026-02-04 | -0.39 |
| 2026-02-03 | -0.40 |
| 2026-02-02 | -0.43 |
| 2026-01-30 | -0.41 |
| 2026-01-29 | -0.40 |
| 2026-01-28 | -0.43 |
| 2026-01-27 | -0.45 |
| 2026-01-26 | -0.46 |
| 2026-01-23 | -0.48 |
| 2026-01-22 | -0.49 |